This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

SCID with Low T- and B-cell NumbersT- 및 B-세포수가 감소된 중증복합면역결핍

ICD-10: D81.1 | Synonyms: T-B- NK+ SCID, RAG1/RAG2 deficiency SCID, Omenn syndrome (some), T-B- cell-reduced severe combined immunodeficiency

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

First description of SCID

The concept of severe combined immunodeficiency (SCID) was established in the 1950s when infants with fatal immunodeficiency accompanied by lymphopenia and thymic aplasia were reported in Switzerland. In 1968, Robert Good first succeeded in treating a SCID patient with bone marrow transplantation, opening a new horizon in treatment.

Classification of the T-B-NK+ type

As lymphocyte subset analysis techniques advanced, a system for classifying SCID according to the presence or absence of T cells, B cells, and NK cells was established. The T-B-NK+ type is a form in which both T cells and B cells are deficient but NK cells are normal or increased, and it was shown in the 1990s to be caused mainly by defects in the RAG1 or RAG2 genes.

Discovery of the RAG genes

In 1990, Schatz and Baltimore discovered the RAG1 and RAG2 genes, which are essential for V(D)J recombination. In 1996, Villa et al. first reported that RAG1/RAG2 mutations cause T-B-NK+ SCID, and subsequently the diverse clinical spectrum of Omenn syndrome and partial loss-of-function RAG variants was elucidated.

Situation in Korea

In Korea, SCID patients are diagnosed and treated at a small number of tertiary medical institutions such as Seoul National University Hospital. Accurate statistics by type are lacking, but RAG1/RAG2-deficient patients have been cumulatively reported on the order of several dozen.

2. Causes

RAG1/RAG2 defects - main cause

The most common cause of D81.1 is loss-of-function mutations in the RAG1 (Recombination Activating Gene 1, 11p13) or RAG2 (11p13) gene. RAG1/RAG2 proteins act as endonucleases that catalyze cleavage of antigen receptor genes during V(D)J recombination. Complete loss-of-function variants cause T-B-NK+ SCID, and partial loss-of-function variants cause a diverse clinical spectrum including Omenn syndrome.

Artemis defect

The Artemis protein (DCLRE1C gene, 10p13) is involved in DNA repair during V(D)J recombination. Artemis deficiency also causes T-B-NK+ SCID and is characterized by increased cellular radiosensitivity.

Other V(D)J recombination defects

Defects in the DNA-PKcs (PRKDC), Cernunnos/XLF (NHEJ1), and DNA Ligase IV (LIG4) genes can also cause T-B-NK+ SCID or a similar phenotype.

3. Genetics

Mode of inheritance

SCID due to RAG1/RAG2 defects follows an autosomal recessive mode of inheritance. The RAG1 and RAG2 genes are located side by side on the short arm of chromosome 11 (11p13).

Variant types and clinical spectrum

Complete loss-of-function (null) variants of the RAG1/RAG2 genes cause T-B-NK+ SCID. Partial loss-of-function (hypomorphic) variants show various phenotypes, including ① Omenn syndrome: a form characterized by hyperactive T cells, erythroderma, eosinophilia, and high IgE, ② atypical SCID, and ③ combined immunodeficiency (CID).

Genotype-phenotype correlation

The lower the residual RAG activity, the closer the phenotype is to typical SCID; the higher the residual activity, the more the form becomes Omenn syndrome or mild immunodeficiency.

4. General epidemiology

Worldwide prevalence

The overall incidence of SCID is estimated at 1 per 50,000–100,000 newborns. T-B-NK+ SCID (including RAG defects) is known to account for about 20–30% of all SCID.

Regional distribution of RAG defects

RAG1/RAG2 variants are distributed worldwide and are not limited to particular ethnicities or regions. There are reports that the frequency of RAG defects is high in some Islamic populations due to specific founder effects.

Status in Korea

In Korea, SCID due to RAG1/RAG2 defects is reported extremely rarely. Patients registered under code D81.1 in the rare disease information of the Korea Disease Control and Prevention Agency (KDCA) are very few. Undiagnosed patients are expected to be identified if newborn screening is expanded.

5. Pathophysiology

Impaired V(D)J recombination

T cells and B cells generate the variable regions that make up the T-cell receptor (TCR) and B-cell receptor (BCR, immunoglobulin), respectively, through recombination of V, D, and J gene segments (V(D)J recombination). The RAG1/RAG2 complex is the key enzyme that recognizes the recombination signal sequences (RSS) between the segments and cleaves the DNA.

Block in lymphocyte development

With RAG1 or RAG2 defects, V(D)J recombination does not occur, so functional TCRs or BCRs cannot be formed. Immature T progenitor cells without a TCR are eliminated in the thymus by negative selection and cannot develop into mature T cells. Similarly, pro-B cells without a BCR in the bone marrow cannot develop into mature B cells. Because NK cells do not require V(D)J recombination, they develop normally, giving the NK+ phenotype.

6. Symptoms

Typical SCID symptoms

Severe recurrent infections begin after 3–6 months of age (after maternal antibodies are depleted). Pneumonia (P. jirovecii, CMV, adenovirus), chronic diarrhea, oral candidiasis, skin infections, sepsis, etc. are the main symptoms. Because there may be fatal reactions even to normal vaccine viruses, live vaccines are absolutely contraindicated.

Symptoms of Omenn syndrome

Omenn syndrome, which occurs with partial loss-of-function RAG variants, shows distinctive symptoms different from SCID. It is characterized by generalized erythroderma, alopecia, chronic diarrhea, lymphadenopathy, hepatosplenomegaly, eosinophilia, and hyper-IgE. Hyperactivated autoreactive T cells attack tissues.

7. Signs

Physical examination findings

Absence of the thymic shadow (chest X-ray), underdeveloped lymphoid tissue (underdeveloped tonsils, nonpalpable lymph nodes), failure to thrive. In Omenn syndrome, generalized erythroderma, alopecia, lymphadenopathy, hepatosplenomegaly are characteristic.

Blood test findings

CBC shows a markedly decreased absolute lymphocyte count (normal infants <3000/μL). Flow cytometry shows marked reduction or absence of both T cells (CD3+) and B cells (CD19+), with NK cells (CD16+/CD56+) normal or increased. In Omenn syndrome, T cells are increased, but all have a hyperactivated memory phenotype (CD45RO+) and an extremely restricted repertoire.

Immunoglobulin findings

Serum IgG, IgA, and IgM are all decreased (after 6 months of age, when maternal IgG is depleted). In Omenn syndrome, IgE is extremely high, and IgG, IgA, and IgM are decreased.

8. Screening

TREC-based newborn screening

Reduced T-cell production is detected early through TREC quantification from dried blood spots. RAG-deficient SCID has extremely low or undetectable TRECs and screens positive.

Complementary KREC testing

To confirm B-cell deficiency, measuring kappa-deleting recombination excision circles (KREC) together with TREC allows more accurate classification of T-B-NK+ SCID.

Family history and prenatal testing

When there is an affected sibling, blood is drawn immediately at birth, and lymphocyte subset testing and RAG1/RAG2 gene analysis are performed.

9. Diagnosis

Immunophenotypic analysis

Flow cytometry confirms the number and proportion of T (CD3+), B (CD19+), and NK (CD16+/CD56+) cells. Measurement of TCR αβ/γδ subsets, CD4+/CD8+ ratio, naive T cells (CD45RA+). T-cell function tests (proliferative response to mitogen stimulation).

Confirmatory genetic testing

Sequencing of the RAG1 and RAG2 genes is the standard confirmatory method. When a RAG defect is suspected but the result is negative, a gene panel of V(D)J recombination-related genes such as Artemis (DCLRE1C), DNA-PKcs (PRKDC), LIG4, and NHEJ1, or whole exome sequencing (WES), is performed.

Prenatal diagnosis

When there is a family history, prenatal diagnosis is made by analysis of the relevant gene after CVS or amniocentesis.

10. Treatment

Hematopoietic stem cell transplantation (HSCT)

The curative treatment is HSCT. Early transplantation (before infections occur, before 3.5 months of age) gives the best results. An HLA-matched sibling donor is best; if unavailable, unrelated donor or haploidentical transplantation is performed. In RAG-deficient SCID, B-cell reconstitution tends to be slower than in ADA-SCID or γc-SCID, so long-term IVIG supplementation may be needed after transplantation.

Supportive care

Protective isolation, IVIG administration, and antibacterial·antifungal·antiviral prophylaxis. Live vaccines absolutely prohibited. Use of CMV-negative irradiated blood products.

Treatment of Omenn syndrome

In Omenn syndrome, immunosuppressive treatment before HSCT (cyclosporine, steroids) is needed to suppress tissue damage by hyperactive T cells.

11. Prognosis

Without treatment

Without HSCT, most die of infection within the first year of life.

Prognosis after HSCT

When diagnosed early through newborn screening, overall survival after HSCT has improved to 90% or more. The prognosis is worse when transplantation is received after infections have progressed. RAG-deficient SCID may have incomplete B-cell reconstitution compared with other types (γc, JAK3 defects), so a higher proportion require long-term immunoglobulin supplementation.

Prospects for gene therapy

Research on RAG1/RAG2 gene therapy is in progress, but it is not yet at the stage of clinical application.

12. Prevention

Newborn screening

TREC (+KREC)-based newborn screening aims at early diagnosis within the first few days of life and linkage to HSCT before infections occur.

Genetic counseling and prenatal diagnosis

When a sibling of an affected child is born, immediate genetic testing and immune function evaluation are performed. Prenatal genetic diagnosis is available for high-risk couples.

Infection prevention

After diagnosis and until HSCT, no live vaccines, Pneumocystis jirovecii prophylaxis, regular IVIG administration, protective isolation, etc. are strictly implemented.

13. References

  1. Schatz DG, Oettinger MA, Baltimore D. The V(D)J recombination activating gene, RAG-1. Cell. 1989;59(6):1035-1048.
  2. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998;93(5):885-896.
  3. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625-655.
  4. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434-446.
  5. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729-738.
  6. Notarangelo LD, Kim MS, Walter JE, Lee YN. Human RAG mutations: biochemistry and clinical implications. Nat Rev Immunol. 2016;16(4):234-246.
  7. Gaspar HB, Qasim W, Davies EG, et al. How I treat severe combined immunodeficiency. Blood. 2013;122(23):3749-3758.
  8. Fischer A, Notarangelo LD, Neven B, Cavazzana M, Puck JM. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers. 2015;1:15061.
  9. Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT. Blood. 2014;123(20):3200-3210.
  10. Lee WI, Kang JH, Kim JM, et al. Clinical and laboratory features of Korean children with primary immunodeficiency disorders. J Korean Med Sci. 2013;28(11):1553-1560.
  11. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med. 1965;273(8):427-432.
  12. Gruber TA, Shah AJ, Hernandez M, et al. Clinical and genetic heterogeneity in reticular dysgenesis. Pediatr Blood Cancer. 2009;53(3):387-391.